Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 1-Year Low – Time to Sell?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares reached a new 52-week low on Thursday . The company traded as low as $21.46 and last traded at $21.7530, with a volume of 1536019 shares traded. The stock had previously closed at $22.90.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ADPT shares. Morgan Stanley boosted their target price on shares of Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Wednesday. JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, BTIG Research reaffirmed a “buy” rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, June 17th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.83.

Adaptive Biotechnologies Stock Performance

The company has a market capitalization of $3.49 billion, a price-to-earnings ratio of -65.93 and a beta of 2.07. The firm has a fifty day moving average price of $17.26 and a 200-day moving average price of $16.13.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business had revenue of $70.87 million during the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the previous year, the firm earned ($0.20) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Insider Activity

In other news, insider Sharon Benzeno sold 154,768 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the transaction, the insider directly owned 221,278 shares in the company, valued at approximately $4,677,816.92. The trade was a 41.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harlan S. Robins sold 386,240 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total transaction of $8,501,142.40. Following the sale, the insider directly owned 1,019,658 shares of the company’s stock, valued at approximately $22,442,672.58. This trade represents a 27.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 920,545 shares of company stock valued at $18,588,281 in the last 90 days. 5.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of large investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd bought a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $28,000. EverSource Wealth Advisors LLC lifted its position in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares during the last quarter. Assetmark Inc. boosted its stake in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Adaptive Biotechnologies in the fourth quarter valued at about $51,000. Finally, Strive Financial Group LLC bought a new position in Adaptive Biotechnologies in the fourth quarter valued at about $52,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.